Literature DB >> 19541715

Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases.

M Gilson1, D Zerkak, J Wipff, D Dusser, A T Dinh-Xuan, V Abitbol, S Chaussade, P Legmann, A Kahan, Y Allanore.   

Abstract

The aims of the present study were to identify prognostic factors for systemic sclerosis (SSc)-related interstitial lung disease and to clarify the possible causative role of manometric oesophageal involvement. Consecutive SSc patients underwent pulmonary function tests and oesophageal manometry. They were included in the study if pulmonary function tests were repeated >12 months after baseline. The primary end-point was a decrease of >or=10% of the predicted value in forced vital capacity (FVC). The secondary end-points were a decrease of >or=15% pred in lung carbon monoxide diffusing capacity (D(L,CO)) and a decrease of >or=20% pred in FVC. Of the 105 patients (45 diffuse SSc; median disease duration 2.0 yrs), 23 (23%) had a FVC of <80% pred, 60 (59%) had a D(L,CO) of <80% pred and 57 (54%) showed severe oesophageal hypomotility at baseline. Over 72+/-46 months, 29 (28%) patients displayed a decrease of >or=10% pred in FVC, 39 (40%) of 98 patients displayed D(L,CO) decline and 19 (18%) patients displayed a decrease of >or=20% pred in FVC. On multivariate analysis, diffuse SSc was a significant predictor for a decrease of >or=10% pred in FVC (p = 0.01). No other predictor of a decrease in pulmonary function was identified. Only diffuse SSc was predictive of a decrease in pulmonary function in this early-SSc cohort. This does not support preliminary data suggestive of a causative role of oesophageal involvement.

Entities:  

Mesh:

Year:  2009        PMID: 19541715     DOI: 10.1183/09031936.00060209

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  13 in total

1.  Interstitial lung disease in South Africans with systemic sclerosis.

Authors:  Philippa Ashmore; Mohammed Tikly; Michelle Wong; Claudia Ickinger
Journal:  Rheumatol Int       Date:  2017-11-28       Impact factor: 2.631

2.  Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value.

Authors:  Serena Vettori; Salvatore Tolone; Domenico Capocotta; Rossella Chieffo; Veronica Giacco; Gabriele Valentini; Ludovico Docimo
Journal:  Clin Rheumatol       Date:  2018-02-13       Impact factor: 2.980

Review 3.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

4.  Oxidative stress in Mexicans with diffuse cutaneous systemic sclerosis.

Authors:  M P Cruz-Domínguez; D H Montes-Cortes; I M Olivares-Corichi; O Vera-Lastra; G Medina; L J Jara
Journal:  Rheumatol Int       Date:  2013-03-02       Impact factor: 2.631

5.  Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort.

Authors:  Shervin Assassi; Roozbeh Sharif; Robert E Lasky; Terry A McNearney; Rosa M Estrada-Y-Martin; Hilda Draeger; Deepthi K Nair; Marvin J Fritzler; John D Reveille; Frank C Arnett; Maureen D Mayes
Journal:  Arthritis Res Ther       Date:  2010-09-02       Impact factor: 5.156

6.  The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis.

Authors:  Tricia R Cottrell; Robert A Wise; Fredrick M Wigley; Francesco Boin
Journal:  Ann Rheum Dis       Date:  2013-04-20       Impact factor: 19.103

7.  Inflammatory profile of induced sputum composition in systemic sclerosis and comparison with healthy volunteers.

Authors:  P Jacquerie; M Henket; B André; C Moermans; D de Seny; F Gester; R Louis; M Malaise; J Guiot
Journal:  Sci Rep       Date:  2021-05-21       Impact factor: 4.379

Review 8.  Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: An introduction by The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS).

Authors:  Henrik Pettersson; Helene Alexanderson; Janet L Poole; Janos Varga; Malin Regardt; Anne-Marie Russell; Yasser Salam; Kelly Jensen; Jennifer Mansour; Tracy Frech; Carol Feghali-Bostwick; Cecília Varjú; Nancy Baldwin; Matty Heenan; Kim Fligelstone; Monica Holmner; Matthew R Lammi; Mary Beth Scholand; Lee Shapiro; Elizabeth R Volkmann; Lesley Ann Saketkoo
Journal:  Best Pract Res Clin Rheumatol       Date:  2021-07-01       Impact factor: 4.991

9.  Pulmonary involvement in systemic sclerosis: A clinical profile.

Authors:  A S Deepa; Roopa Premanand Rachel; Priya Ramchandran; Uma Devaraj; S Abhilash Arnold; Vineeta Shobha; George D'souza
Journal:  Lung India       Date:  2016 Mar-Apr

10.  Scleroderma-related interstitial lung disease.

Authors:  Sally Suliman; Abdalhamid Al Harash; William Neil Roberts; Rafael L Perez; Jesse Roman
Journal:  Respir Med Case Rep       Date:  2017-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.